Bioavailability of Symbicort pMDI with Spacer

Phase 1, randomised, open-label trial of budesonide and formoterol in asthma and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at 24 hours and Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at 24 hours. Started Nov 2016; status: completed.